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Abstract 
 
Tacrolimus is a widely used immunosuppressant for prevention of allograft rejection and is 
included in the most common initial immunosuppression regimens for paediatric kidney 
transplant patients. However, due to its narrow therapeutic range and large interindividual 
pharmacokinetic variability therapeutic drug monitoring is routinely performed. The aim of 
this study was to develop a population pharmacokinetic model of twice daily immediate-
release tacrolimus in paediatric kidney transplant patients, identify factors that explain 
variability and optimize and individualize the dosing guidelines.  
This was a retrospective study of whole blood trough concentration-vs.-time data for 
tacrolimus in a population of eighty-five paediatric kidney transplant patients from the 
Children's Memorial Health Institute in Warsaw, Poland in collaboration with UCL School 
of Pharmacy, London, UK. The data management was executed using R software version 
3.3.2. Population pharmacokinetic modelling was performed in the NONMEM 7.3 package 
through a graphical user interface Pirana 2.9.6. Two analysis methods within the 
NONMEM package were used - first order conditional estimation with interaction and 
simulation. Goodness-of-fit plots and prediction and variability corrected visual predictive 
check were used to validate the model.  
The data best fit a pre-described two-compartment model by Zhao et al. with total body 
weight, CYP3A5 polymorphism and haematocrit levels identified as covariates. The model 
incorporated first-order absorption, lag time and an additive model was used for residual 
variability. Due to insufficient information on CYP3A5 genotype and haematocrit in our 
dataset we simplified Zhao’s model and later improved it by including prednisone dose as 
an additional covariate. The final model was shown to be fairly robust since the results of 
prediction and variability corrected visual predictive check were mostly within the 
simulated intervals. 
The validated population pharmacokinetic model was used to simulate the current dosing 
regimen of tacrolimus for the first month of therapy in paediatric kidney transplant 
patients. The results showed that it is not optimal for achieving the required concentration 
range as heavier children are overexposed and patients with lower body weight are 
underexposed. Therefore, we proposed improved dosing guidelines for tacrolimus in 
paediatric kidney transplant patients dependent on weight and concomitant daily 
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prednisone dose. Information on genotype and haematocrit levels of the studied population 
would add to the accuracy of the model since assumptions and simplifications of the model 
have been made. For future studies and further optimization of tacrolimus dosing 
guidelines it would be interesting to see whether the number of samples per individual and 
sampling schedule should be optimized instead of routinely sampling immediately prior to 
the next dose thus measuring only trough levels. 
Key words: tacrolimus, population pharmacokinetics, NONMEM, paediatrics, kidney 
transplant recipients 
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Povzetek 
 
Takrolimus je imunosupresiv, ki spada v skupino kalcinevrinskih inhibitorjev in se že 
desetletja uporablja kot preventiva za preprečevanje zavrnitve presadka (predvsem jeter, 
ledvic in srca) ter za zdravljenje, ko zavrnitev že nastopi in ostali imunosupresivi, na 
primer ciklosporin, niso več učinkoviti. Takrolimus je sestavni del najpogostejših 
imunosupresivnih režimov zdravljenja pri pediatrični populaciji s presajeno ledvico, 
vendar ima ozko terapevtsko okno in veliko intra- ter interindividualno variabilnost, kar 
lahko privede do subterapevtskih ali toksičnih koncentracij v krvi. Med zdravljenjem s 
takrolimusom je tako potrebno redno spremljanje najnižje koncentracije v polni krvi, saj 
lahko prenizke koncentracije povzročijo zavrnitev presajenega organa, previsoke pa 
povečajo verjetnost okužb ter neželenih učinkov, zlasti hipertenzije, hiperglikemije, 
nefrotoksičnosti, tremorja, slabosti ter vplivanja na delovanje ledvic. 
Kadar so tarčna populacija farmakokinetične raziskave otroci v kritičnem stanju in je iz 
etičnega ter zdravstvenega vidika onemogočeno zbiranje večjih količin podatkov, se za 
študijo največkrat uporabijo pristopi populacijske farmakokinetike, ki je cenejša in 
učinkovitejša alternativa tradicionalni farmakokinetični raziskavi. Poznamo več metod 
modeliranja znotraj populacijske farmakokinetike, ena pogostejših pa je nelinearni model 
mešanih učinkov v okviru programskega paketa NONMEM. 
Namen naše študije je bil razviti populacijski farmakokinetični model za peroralni režim 
odmerjanja takrolimusa s takojšnjim sproščanjem dvakrat na dan pri otrocih s presajeno 
ledvico. Poskusili smo prepoznati sočasne spremenljivke, ki vplivajo na farmakokinetiko 
takrolimusa ter jih vključiti v končni model, ki smo ga uporabili za optimizacijo in 
individualizacijo trenutnih smernic odmerjanja takrolimusa v zgodnjem obdobju po 
presaditvi pri pediatrični populaciji s presajeno ledvico.  
Izvedli smo retrospektivno raziskavo najnižjih koncentracij takrolimusa v polni krvi 
petinosemdesetih otrok s presajeno ledvico, ki so bili hospitalizirani v Children's Memorial 
Health inštitutu v Varšavi na Poljskem, delo pa je potekalo v sodelovanju z UCL School of 
Pharmacy v Londonu v Veliki Britaniji. Podatke iz bolnišnice smo analizirali v programu 
Rstudio (verzija 3.3.2.), populacijsko farmakokinetično modeliranje pa izvedli v 
programskem paketu NONMEM 7.3 preko grafičnega uporabniškega vmesnika Pirana 
2.9.6. Znotraj programskega paketa NONMEM smo uporabili dve analitični metodi: 
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pogojno ocenjevanje prvega reda z interakcijo ter simulacijo. S prvo smo dobili oceno 
največjega verjetja parametrov, preko katerega se ocenjuje vrednost objektivne funkcije 
(OFV), ki služi kot eden izmed kriterijev za izbiro najboljšega modela.  
Podatki iz bolnišnice so vsebovali le najnižjo koncentracijo takrolimusa v polni krvi in ne 
polnega farmakokinetičnega profila, zato smo naš model razvili s pomočjo literaturnih 
farmakokinetičnih modelov ter ga dopolnili s potencialnimi sočasnimi spremenljivkami (na 
primer sočasna uporaba ostalih zdravil, starost, spol, podatki o donorjih …).  
Končni model smo ovrednotili s prikazi grafičnih prileganj (goodness-of-fit plots) ter z 
metodo vizualnega vrednotenja populacijskih farmakokinetičnih modelov (visual 
predictive check) ter ga uporabili za simulacijo odmerjanja takrolimusa v skladu trenutnimi 
smernicami za odmerjanje v zgodnjem obdobju po presaditvi pri otrocih s presajeno 
ledvico (0.3 mg/kg/dan v dveh odmerkih). Na podlagi te simulacije smo nato simulirali več 
različnih algoritmov odmerjanja takrolimusa z namenom zagotavljanja koncentracij znotraj 
ciljne najmanjše koncentracije takrolimusa neposredno po presaditvi. 
Zhao in sodelavci so objavili dvoprostorni populacijski farmakokinetični model 
takrolimusa z aditivnim tipom napake, prvim redom absorpcije ter časovnim zamikom pri 
absoprciji ter prepoznali telesno težo, vrednost hematokrita ter CYP3A5 polimorfizem kot 
sočasne spremenljivke v kovariatnem modelu. Ugotovili smo, da model ustrezno opisuje 
farmakokinetiko takrolimusa pri naših pacientih, vendar smo ga zaradi manjkajočih 
podatkov o genotipu CYP3A5 in hematokritu naših pacientov morali poenostaviti. V 
kovariatni model je od testiranih sočasnih spremenljivk dodatno vstopil le dnevni odmerek 
prednizona – sočasno zdravljenje s prednizonom je namreč znižalo biološko uporabnost 
takrolimusa za največ 67 % in statistično značilno izboljšalo prileganje modela izmerjenim 
koncentracijam takrolimusa. Končni model so opisali sledeči parametri: očistek (Cl), 
volumen osrednjega prostora (V2), distribucijski očistek (Q), volumen stranskega prostora 
(V3) ter konstanta absorpcije (Ka). 
S prikazi grafičnih prileganj ter z metodo vizualnega vrednotenja populacijskih 
farmakokinetičnih modelov smo potrdili, da je model robusten, saj so bili rezultati 
večinoma znotraj simuliranih vrednosti pri vizualni analizi. Vsekakor bi model lahko 
izboljšali, če bi imeli podatke o genotipu CYP3A5 in hematokritu. 
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Simulacija odmerjanja po trenutnih smernicah za pediatrične paciente s presajeno ledvico 
zgodaj po presaditvi je pokazala, da so otroci z večjo telesno maso izpostavljeni 
previsokim, bolniki z manjšo telesno maso pa prenizkim odmerkom takrolimusa. Ciljna 
najnižja koncentracija takrolimusa v polni krvi v zgodnjem obdobju po presaditvi je 
namreč 10 – 15 ng/ml, zato smo za doseganje te izdelali optimizirano preglednico 
odmerjanja, odmerek pa se spreminja v skladu s telesno maso posameznika in sočasnim 
dnevnim odmerkom prednizona.   
Pacienti v poljski bolnišinci so večinoma prejemali tacrolimus s takojšnjim sproščanjem - 
Prograf®, ki se jemlje vsakih 12 ur, najmanjši odmerek, ki je dostopen na trgu pa je 0,5 
mg. Preglednico odmerjanja smo zato prilagodili in zagotovili, da je odmerjanje dejansko 
izvedljivo. S simulacijo odmerjanja takrolimusa vsakih 12 ur po prilagojeni shemi smo 
dobili mediano simuliranih vrednosti najmanjše koncentracije v polni krvi znotraj 
terapevtskega okna pri vseh pacientih.  
Potrebno je izpostaviti, da so optimizirani začetni odmerki takrolimusa uporabni le v 
zgodnjem obdobju po presaditvi, ko je terapevtsko okno 10 – 15 ng/ml, kasneje pa se 
stremi k nižjim koncentracijam. Prav tako so rezultati naše študije uporabni le za 
takrolimus s takojšnjim sproščanjem, ki se odmerja dvakrat na dan (Prograf®), študija pa 
je temeljila na pacientih kavkazijske rase, zato so potrebne dodatne raziskave za 
ekstrapolacijo rezultatov na pripadnike drugih ras.  
V nadaljnjih študijah bi lahko s pomočjo paketa PopED v programskem okolju R preverili 
optimalni čas vzorčenja ter število odvzetih vzorcev. V skladu s trenutnimi smernicami se 
namreč jemlje vzorce takrolimusa tik pred naslednjim odmerkom, tako se dobijo vrednosti 
najnižje koncentracije v polni krvi. 
Zavedati se moramo, da je bila magistrska naloga v osnovi raziskava in silico, zato bi se 
morala njena uporabnost preveriti še v dejanski klinični praksi, končni cilj pa je izboljšanje 
izidov zdravljenja pri otrocih s presajeno ledvico. 
 
 
 
Ključne besede: takrolimus, populacijska farmakokinetika, NONMEM, otroci, presajena 
ledvica  
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1  Introduction 
 
1.1 Tacrolimus 
 
1.1.1 Brief overview  
 
In the early 1980s Japan’s Fujisawa Pharmaceuticals performed a variety of tests to 
discover novel immunosuppressive substances with inhibitory effects on IL-2 production 
from the fermentation broth of Streptomyces. In 1984, this screening led to the discovery of 
a strain of Streptomyces tsukubaensis No. 9993 producing a potent neutral macrolide 
immunosuppressive agent labelled with a code number FK-506, nowadays known as 
tacrolimus (TAC) (1,2). Figure 1 presents the chemical structure of TAC.  
 
 
Figure 1. Chemical structure of tacrolimus (FK-506) (1).  
 
Further experiments showed that TAC inhibited proliferative response of lymphocytes to 
alloantigen stimulation, the expression of IL-2 receptor, the cytotoxic T cell generation and 
the production of cytokines such as IL-2, IL-3 and IFN-γ at non-toxic concentrations. 
Moreover, in vitro tests demonstrated that TAC suppressed the above-mentioned processes 
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at about hundred times lower concentrations than cyclosporin, an immunosuppressant from 
the calcineurin inhibitor group (2). Later, in vivo rat studies suggested that TAC can both, 
suppress the ongoing processes of the immune response after the disease has been initiated, 
as well as prevent the activation of the immune response itself (3). This was also tested in 
humans where tacrolimus was used either for primary immunosuppression to prevent 
rejection of liver, kidney and pancreas grafts or as a salvage therapy where graft recipients 
under conventional immunosuppression with cyclosporin had rejection episodes or drug-
related toxicity. In a study by Starzl et al., the performance of TAC was promising since no 
rejection of the liver, kidney or pancreas fresh grafts was encountered and rescue therapy 
was successful in 7 out of 10 people (4). A comparison between cyclosporin and 
tacrolimus in adult liver transplant patients associated tacrolimus with a reduction of acute, 
refractory acute and chronic rejection episodes together with a lower concomitant 
corticosteroid usage (5). The latter being especially important in paediatrics where a 
concomitant use of prednisone was linked to growth retardation (6).  
According to US Scientific registry of transplant recipients data, in 2017, TAC was 
included in the most common initial immunosuppression regimens for paediatric kidney 
transplant patients, 57.6 % of them prescribed TAC, mycophenolate mofetil (MMF) and 
steroids, followed by 32.9 % receiving TAC and  MMF at the time of transplantation. The 
same report lists congenital anomalies of the kidney and urinary tract, focal segmental 
glomerulosclerosis, and glomerulonephritis as main reasons leading to end-stage kidney 
disease in paediatric patients (7). 
Despite all the benefits, TAC has a narrow therapeutic index, thus lower blood 
concentrations can trigger rejection episodes whereas high concentrations may lead to 
drug-related toxicity (8). Several adverse effects have been reported such as impaired renal 
function, changes in glucose metabolism (hyperglycaemia, diabetes mellitus), neurological 
complications (tremor, paraesthesia), hypertension, gastrointestinal disorders (diarrhoea, 
nausea, vomiting) and an increased risk for infectious complications. Most of the adverse 
effects were dose-dependent and their incidence decreased over time when a reduction in 
the dose of TAC was made (5, 9, 10).  
Hirsutism, gingivitis and gingival hypertrophy, frequently reported side effects of 
cyclosporin, were rarely observed in patients receiving TAC (5,10), however, pruritus and 
alopecia were more commonly associated with TAC (10). 
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Not only is TAC a drug with a narrow therapeutic index, its pharmacokinetics (PK) is 
affected by multiple factors such as body weight (11,12), age (13,14), haematocrit (11,15), 
concomitant drugs (16), ethnicity (17) and cytochrome P450 (CYP) 3A5 genotype (11). 
Hence, therapeutic drug monitoring (TDM) for TAC is routinely performed (8,18).  
 
1.1.2 Mechanism of action 
 
TAC exerts its effects primarily by altering gene expression in target cells (19). In 
particular, inhibiting IL-2 gene transcription in T-helper (Th) cells though similar effects 
on IFN-γ and IL-3 were reported (20).   
Normally, interaction of major histocompatibility complex-bound antigen with a Th cell 
receptor results in the activation of phospholipase C, generating free intracellular calcium 
(Ca2+). The Ca2+ binds to calmodulin which in turn binds to and stimulates a protein 
phosphatase, calcineurin (20,21). This leads to the activation of different transcription 
factors (20) such as the cytoplasmic component of nuclear factor of activated T-cells (NF-
ATc) (19). Calcineurin dephosphorylates NF-ATc, translocating it to the nucleus where it 
combines with the nuclear counterpart, NF-ATn. The complex then binds to the DNA, 
specifically to the promoter of the IL-2 gene, leading to the IL-2 expression (19). 
TAC binds to a 12 -kilodalton cytosolic FK506-binding protein (FKBP12), a member of 
the immunophilin family - a group of proteins acting as intracellular receptors for 
immunosuppressants such as TAC and cyclosporin (19–21). Then a FKBP12-TAC 
complex binds to and inhibits the calcium/calmodulin-dependent protein phosphatase 
calcineurin, thereby preventing the translocation of NF-ATc to the nucleus thus inhibiting 
the Ca2+-dependent activation of Th cells and production of IL-2 (19,20). Figure 2 below 
depicts the key steps in the mode of action of TAC. 
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Figure 2. Mechanism of action of tacrolimus (FK506). Reproduced from (19).  
 
 
1.1.3 Pharmaceutical form and therapeutic indications 
 
Tacrolimus can be given orally, by intravenous (IV) injection or as an ointment (20). The 
latter being used in moderate to severe atopic dermatitis (eczema) where the inflammation 
of the skin is uncontrolled by topical glucocorticoids (20,22).  
IV application is recommended for patients who cannot tolerate oral formulations, 
otherwise oral route of administration is preferred. Therapeutic indications for both oral 
and IV tacrolimus stated in the summary of product characteristics (SmPC) are: 
• prophylaxis of transplant rejection in liver, kidney and heart allograft recipients  
• treatment of allograft rejection resistant to other immunosuppressants (23)  
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1.1.4 Pharmacokinetics 
 
Two formulations of TAC are available, immediate- (e.g. Prograf®) or prolonged-release 
(e.g. Advagraf®). The key PK data provided in the chapters below will be based on 
immediate-release TAC, Prograf®. 
 
1.1.4.1 Absorption and distribution 
 
TAC is absorbed throughout the gastrointestinal tract (GIT) (24) with large interindividual 
variability (IIV) reported both in the rate of absorption as well as absolute bioavailability 
(25,26). The mean oral bioavailability of TAC is poor, only around 25 % (24,26) varying 
from 4 % to 89 % (25).  
Food reduces the rate and extent of absorption, the effect being most apparent after a high-
fat meal (27). In order to achieve maximal absorption, it is best to take tacrolimus on an 
empty stomach, at least 1 hour before or 2 to 3 hours after a meal (24).  
Nagase et al. demonstrated that TAC binds strongly to erythrocytes (95 – 98 %) in the 
systemic circulation of dogs, monkeys and humans (28). In humans this results in an 
approximate 20:1 concentration ratio between whole blood and plasma (24). The 
distribution is affected by drug concentration, temperature and haematocrit (28). In plasma, 
more than 98.8 % of TAC is bound to various proteins such as α1-acid glycoprotein, 
lipoproteins, globulins and albumin (24,28). 
Tacrolimus is extensively distributed in the body, the steady state volume of distribution 
(Vss) based on plasma concentrations of healthy volunteers being roughly 1300 l whereas 
data based on whole blood concentrations estimates the Vss to 47.6 l (24).  
 
1.1.4.2 Metabolism and elimination 
 
A study by Möller et al. showed that following IV and oral administration less than 0.5 % 
of the unchanged TAC was detected in faeces and urine (29), indicating that TAC is almost 
completely metabolised, primarily in the liver by CYP3A isoenzymes and also in the 
intestinal wall (24). Most of the radioactivity from 14C-labelled tacrolimus was found in 
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faeces and less than 3 % in the urine, suggesting the main path of elimination is biliary 
excretion (29). 
Tacrolimus is a low clearance substance (24) with the mean total body clearance 
equivalent to 3 % of the liver blood flow (29). Studies have shown that paediatric 
population has a higher clearance per unit of body weight than adults (26,30), a study by 
Wallemacq et al. observed up to twice as high clearance per unit of body weight in 
paediatric liver transplant recipients than in adult liver allograft recipients (24,26). 
Younger children tend to require higher doses per kg of body weight to achieve the desired 
concentration range (13,14,30). Generally, doses required in paediatrics are around 1.5 – 2 
times higher per kilogram body weight than the adult doses to reach similar blood levels 
(24).   
Higher TAC clearance rates following transplantation may occur due to corticosteroid-
induced metabolism or low haematocrit and protein levels, resulting in an increase of the 
unbound fraction of TAC (24).  
 
1.1.5 Therapeutic dosing guidelines and individualization  
 
Our work will focus on paediatric kidney transplant patients receiving immediate-release 
tacrolimus, Prograf®. Therefore, in this section, we will only describe therapeutic dosing 
guidelines and therapeutic drug monitoring for the above-mentioned study population and 
medicine. 
SmPC for Prograf recommends the starting oral dose of 0.30 mg/kg/day, administered in 
two divided doses every 12 hours, for prophylaxis of kidney transplant rejection in 
children. Further dose adjustments are many times needed since the improvement in the 
condition of the patient can alter the PK of TAC. Generally, Prograf doses are usually 
reduced over time (24).  
As previously mentioned, (Chapter 1.1.1 and 1.1.4), there is a large interindividual 
variability in the PK profile of tacrolimus, especially in absorption and clearance, making 
it hard to fit every individual in the same dosing scheme. Initial doses are only a rough 
guideline. Instead, treatment regimen should primarily be based on tolerability and clinical 
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assessments of adverse effects or potential rejection in each patient individually aided by 
therapeutic drug monitoring (18,24).  
It was shown that TAC whole blood trough concentrations highly correlate with AUC0-12h 
(24,31,32) and that TAC trough levels were associated with clinical outcomes in the first 
month post-transplant (33). Therefore, monitoring of TAC whole blood trough 
concentrations is a good estimate of systemic exposure and is routinely performed. Trough 
levels should be monitored twice weekly immediately post transplantation and then 
periodically during maintenance therapy. Monitoring should be applied after dose 
adjustment, change in immunosuppression regimen or after initiation or discontinuation of 
treatment with potentially interacting drugs (24).  
The target range for tacrolimus whole blood trough concentration in paediatric kidney 
transplant patients is approximately 10 – 15 ng/ml in the first month post transplantation 
and then subsequently reduced to 5 – 10 ng/ml during the maintenance therapy (34).  
 
1.2 Population pharmacokinetics and modelling 
 
Population pharmacokinetics (PopPK) is an integral part of clinical pharmacology that 
identifies and describes relationships between individual’s physiologic attributes and 
observed drug exposure or response. It does so by using a collection of mathematical 
functions that can illustrate the relationship between drug concentration and time. PopPK 
uses models to assess typical PK parameters, their interindividual variability (IIV) and the 
residual variability in drug concentration (35,36).   
The basic building block of a PK model is a compartment – a part of the body where the 
drug is kinetically homogenous and well mixed (one concentration can represent the whole 
compartment at a given time point). Usually the PopPK models differ in the number of 
compartments and the way they are interconnected by the rate constants (e.g. k12 and k21) 
or intercompartment clearance (e.g. Q). There are two kinds of compartments - central 
compartment which can be thought of as blood and highly perfused organs and peripheral 
compartments which are typically theoretical concepts and do not necessarily represent a 
particular body region (36).   
A model is an oversimplified representation of otherwise complex human body and all the 
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mathematical calculations for predictions and estimations are imperfect. Therefore, the 
dosing regimen predicted for a patient will always differ to some extent from the optimal, 
real one (35,36). From the clinical point of view, the main purpose of a PopPK model is to 
provide dosing guidelines, especially initial dosage regimens, and to optimize/individualise 
the drug therapy (35,37).  
The importance of an individual patient is highlighted in the characterisation of variability. 
Each person has his/her own PK parameters affected by covariates such as age, height, 
weight, co-medication, comorbidity, gene expression, etc. After the PopPK identifies these 
factors influencing the PK behaviour of a certain drug and with the sufficient knowledge of 
patient’s characteristics, a PK profile of any individual can then be predicted (35–37). 
The two sources of variability when dealing with biological data that can explain the 
difference between the expected and observed values are IIV or between-subject variability 
and residual (intraindividual) variability. The first arises from the fact that people are, 
simply said, different whereas the latter includes inter-occasion variability, potential 
misspecification of the model and errors in the assay, dosing and time of measurement. 
Residual variability is always present, unpredictable and it is defined as unexplained 
variability after other sources of variability have been accounted for (35, 37–39). Unlike 
the traditional PK studies where the study design and strict inclusion and exclusion criteria 
minimize the variability, PopPK emphasizes the importance of the origin of the variability 
(IIV, residual) by identifying and quantifying it in a PopPK model (35,37).  
To perform the PopPK analysis and interpret the results experienced pharmacokineticists 
and pharmacometricians are required (35). Additional key differences between traditional 
and PopPK studies are summarized in Table I below. 
Table I. Comparison of a traditional PK and PopPK study (35,37,39). 
ASPECT TRADITIONAL PK PopPK 
Population Healthy volunteers or highly 
selected patients 
Actual patients treated with 
the investigated drug 
(population of interest) 
Data Dense (≥6 samples per 
subject); 
From the studied population 
Sparse (one or few samples 
per subject) or/and dense; 
Heterogenous from various 
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(experimental); 
Evaluated individually 
sources (observational and 
experimental); 
Evaluated simultaneously 
for all individuals 
Costs Expensive Cost-effective 
Orphan populations 
(neonates, HIV-infected, 
elderly, pregnant women, 
cancer patients …) 
Ethical/medical 
considerations about 
including them in a study 
Sampling in these 
populations is limited and a 
part of routine monitoring; 
PopPK is a perfect tool 
Group size Small Big 
Sampling times Pre-determined Can be random, part of 
routine monitoring 
 
There are many different modelling methods in PopPK (e. g. naive pooled data, standard 
two-stage approach) (37) but our study comprised of working with nonlinear mixed effects 
modelling (NLMEM) and the underlying software. Therefore, the following review will be 
limited only to the methods used in this study. 
 
1.2.1 Nonlinear mixed effects modelling (NLMEM) 
 
NLMEM consists of two parts – “nonlinear” and “mixed effects”. The first means that the 
dependent variable (usually concentration) is not in a linear relationship with independent 
variables (eg. time) and model parameters. The typical concentration-time PK profile of a 
drug within the population is described by a structural model. “Mixed effects” refers to the 
two types of effects on parameters in a model, fixed effects and random effects.   
Fixed effects are expressed as average (typical) values of PK parameters in a population 
and they can be a function of known, observable characteristics of an individual such as 
weight, age, sex, renal function etc. In this case the characteristics act as covariates which 
are patient specific factors that can affect the PK or PD of a drug and help explain the IIV 
and their impact on parameters is called fixed covariate effect. For instance, if volume of 
distribution (with its typical value) is proportional to weight and we define that in the 
model (this would now be a covariate model where weight explains a part of variability in 
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volume of distribution), we would say that weight has a fixed effect on volume of 
distribution. Random effects are the amount of PK variability that is not described by the 
fixed effects and cannot be predicted in advance. They include IIV and residual variability 
(35, 37–39).   
Fixed effects in a model are expressed as theta (θ), a typical value which is the same for 
every subject and is generally estimated from the data. Eta (η) represents interindividual 
variability and it is a random variable, normally or log-normally distributed with the mean 
of 0 and a variance of ω2 (η ∈ N(0, ω2)). Epsilon (ε) represents residual variability and it is 
also a random variable, normally distributed with the mean of 0 and a variance of σ2 (ε ∈ 
N(0,σ2)). η shows the difference between individual’s parameter value and the typical 
population value whereas ε reflects the difference between the observed data for a patient 
and the model’s prediction (36,38).   
Both IIV and residual variability can be incorporated in a model as shown in Table II. A 
combination of additive and proportional error model is also possible. For demonstration 
purposes we defined IIV on PK parameter clearance, whereas Y in residual error represents 
observed data (e. g. concentration) and TY the true value of Y (e. g. individually predicted 
concentration) (38,39). 
Table II. Incorporation of error structures in the model (38,39).  
Variability model IIV Residual 
Additive Clearance = 𝜃𝐶𝐿 + 𝜂(𝐶𝐿) Y = TY + ε 
Proportional Clearance = 𝜃𝐶𝐿 ∗(1+ 𝜂(𝐶𝐿)) Y = TY∗(1+ ε) 
Log-normal Clearance = 𝜃𝐶𝐿 ∗ 𝑒𝜂(𝐶𝐿) Y = TY∗ 𝑒ε; Due to 
Taylor’s expansion, the 
definition is not 
straightforward, for 
additional info see Fisher et 
al., 2007 (38). 
 
To sum up, there are five important elements of NLMEM (39): 
• Data (should be examined closely to assure accuracy, identify outliers, basis for 
further analysis) 
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• Structural model (describes typical concentration – time PK profile of a drug within 
the population with the use of mathematical functions) 
• Statistical model (explains the IIV and residual variability) 
• Covariate model (identifies patient’s characteristics (covariates) accounted for a 
part of PK variability) 
• Modelling software (merges data and models, computes the PK parameters through 
embedded estimation methods) 
 
1.2.2 NONMEM 
 
For the purposes of our study we used NONMEM 7.3.0 (NON-linear Mixed Effects 
Modelling), modelling software for estimation of parameters in mixed-effects models. It is 
a widely used tool in pharmaceutical industry for PK/pharmacodynamic (PD) analysis. 
There are various estimation methods implemented in NONMEM (Laplacian method, first-
order conditional estimation method (FOCE) with or without interaction, first-order 
method (FO)) but due to complex statistical and mathematical backgrounds of the 
algorithms used we will not go into details but would rather refer readers to Wang et al., or 
Ette et al. where the methods are explained into details (40,41).   
In our work we used FOCE-I where the model can be linearized around conditional 
estimates of the interindividual random effects based on FO Taylor expansion with respect 
to random variables η and ε. A single objective function value is being minimized yielding 
a similar effect as with iteration (40,41). When estimating parameters, NONMEM 
minimizes -2 log likelihood (L), named objective function value (OFV), which maximizes 
the likelihood that the predicted observations (?̂?𝑖) would have been observed (Y). 
 
−2 𝑙𝑜𝑔(𝐿)  =  𝑛𝑙𝑜𝑔(2𝜋) + ∑ (𝑙𝑜𝑔(𝑛𝑖=1 σ𝑖
2)  + 
(𝑌𝑖−?̂?𝑖)
2
 σ𝑖
2 )   Equation 1 
 
Since 𝑛𝑙𝑜𝑔(2𝜋) is a constant that cannot be minimized, NONMEM tries to minimize 
∑ (𝑙𝑜𝑔(𝑛𝑖=1 σ𝑖
2)  +  
(𝑌𝑖−?̂?𝑖)
2
 σ𝑖
2 ). Since (𝑌𝑖 − ?̂?𝑖)
2 is weighted by variance we could maximize 
the variance but at the same time the bigger the variance the bigger the term log(σ𝑖
2) 
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resulting in  a greater -2log(L). This leads to the fact that minimizing -2log(L) is the same 
as minimizing (𝑌𝑖 − ?̂?𝑖)
2 if the variance model does not change from observation to 
observation (38).  
OFV is a single value providing a general overview of how close model predictions are to 
the actual data (maximum likelihood = lowest OFV = best fit). A routine test for statistical 
significance of an added parameter to the model is the likelihood ratio test. The two models 
need to be nested (a subset of each other) and have a different number of parameters. This 
is especially useful when comparing covariate models to base models (38,39). The 
distribution of −2𝑙𝑜𝑔(𝐿1/𝐿2) follows a chi-square distribution (42). If the addition of 1 
parameter (covariate) changes the OFV (−2 𝑙𝑜𝑔(𝐿)) between the two models by more than 
3.84 then the parameter is significant at p < 0.05 (38).  
In addition to OFV, one could measure the importance of a specific covariate with the use 
of conditional weighted residuals (CWRES) which is a diagnostic tool calculated as the 
FOCE approximated difference between individual’s data (𝑦𝑖⃑⃑⃑  ) and predicted data by the 
model (𝐸𝐹𝑂𝐶𝐸(𝑦𝑖⃑⃑⃑  )) normalized by the square root of the covariance of that data (43). It 
gives us relevant information about the fit of a PopPK model to the data using FOCE 
estimation method. 
𝐶𝑊𝑅𝐸𝑆 =
𝑦𝑖⃑⃑  ⃑−𝐸𝐹𝑂𝐶𝐸(𝑦𝑖⃑⃑  ⃑)
√𝐶𝑜𝑣𝐹𝑂𝐶𝐸(𝑦𝑖⃑⃑  ⃑)
        Equation 2  
 
CWRES should be normally distributed with the mean of 0 and variance one, N(0, 1) (43). 
This means that approximately 95 % of the CWRES values should be within 2 standard 
deviations of the mean (44), in our case 0 ± 2. If the model fits the data well, we expect 
CWRES to indicate that by following a normal distribution with mean zero and variance 
one. When the distribution greatly deviates from the expected it indicates model 
misspecification (43). CWRES is usually evaluated graphically (43), e. g. if we suspect 
that a certain co-medication could be a potential covariate in a model, we could visually 
assess the CWRES values of people receiving that drug. If their CWRES values differ a lot 
from 0 ± 2 distribution, it means that the model doesn’t fit the data of these people 
indicating that co-medication could be included as a potential covariate in the model to 
improve the fit.  
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2 Aim of the study 
 
Tacrolimus is a widely used maintenance immunosuppressant for prevention of allograft 
rejection in kidney transplant recipients. Due to its narrow therapeutic range an absence of 
therapeutic effects leading to organ rejection can occur when concentrations are too low, as 
well as drug toxicity when concentrations are too high. 
This study is a result of collaboration between UCL School of Pharmacy, London, UK, and 
Children's Memorial Health Institute in Warsaw, Poland, and its aim is to develop a 
validated population pharmacokinetic model for twice daily immediate-release tacrolimus 
in paediatric kidney transplant patients, identify factors that influence the PK of TAC and 
use it to optimize and individualize the current tacrolimus dosing guidelines for paediatric 
kidney transplant population during the early post-transplant period. 
First, we will use R version 3.3.2 to transform the hospital’s dataset into a useful form 
which can be analysed. Then we will perform a literature review to find a model that will 
best fit our data. We will try to optimize it with inclusion of potential covariates. The two 
methods we will use are first order conditional estimation with interaction and simulation 
in the NONMEM 7.3 software package. 
Once we develop the final PK model, we will create a population of virtual patients in R 
and then perform a simulation in NONMEM where each virtual patient will receive 
tacrolimus in accordance with the current dosing guidelines. The results will be inspected 
in R to see whether concentrations are within the therapeutic range. If not, we will 
optimize the dosing regime, simulate again, validate and propose improved tacrolimus 
dosing chart for paediatric kidney transplant recipients.  
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3 Materials and methods 
 
3.1  Population and data 
 
Data for our retrospective cohort study were provided by Children's Memorial Health 
Institute in Warsaw, Poland. It consisted of 85 Caucasian paediatric kidney transplant 
patients (forty-five males and forty females) with various primary diseases, including 
congenital nephrotic syndrome, nephrosclerosis, glomerulonephritis and renal hypoplasia 
that all led up to kidney transplantation.  
Inclusion criteria: 
• Age <18 
• Kidney transplant recipient 
• Treatment with tacrolimus 
Exclusion criteria: 
• Incomplete dosing history 
• Incomplete time records 
Once we gained the access to the data, we transformed it into a useful form that can be 
analysed. The process included sorting, merging and subsetting datasets as well as 
aggregating and reshaping data. The dataset contained information on tacrolimus dosing 
(date, amount, tradename, formulation) and tacrolimus whole blood trough concentrations. 
In addition, records regarding patient’s height, weight, age, sex, transplantation date, 
donor, vaccination, co-medication, haemoglobin, serum creatinine, comorbidities, blood 
pressure etc. were provided. Tacrolimus was given in two formulations – immediate-
release Prograf® taken per os twice daily and prolonged-release Advagraf® taken per os 
once a day. The samples were collected 12 hours (Prograf®) or 24 hours (Advagraf®) after 
the last dose and immediately prior to the next one and in total 1305 whole blood trough 
concentration-time points were analysed. 
Since glomerular filtration rate (GFR) is a very powerful indicator of kidney function and 
it was not provided in the dataset we estimated it with the help of surrogate marker serum 
creatinine using the Schwartz formula presented in Equation 3 (45).  
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eGFR[ml/min/1.73m2] = 0.413 ∗
ℎ𝑒𝑖𝑔ℎ𝑡[𝑐𝑚]
𝑠𝑒𝑟𝑢𝑚 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒[𝑚𝑔/𝑑𝑙]
   Equation 3 
 
3.2 Population pharmacokinetic model 
 
PopPK modelling was performed in the NONMEM 7.3 package. As a graphical user 
interface for NONMEM we used Pirana 2.9.6. We had to transform our dataset in R 
(version 3.3.2) into a file recognizable by NONMEM. Basic steps included: 
• Getting our data ready and saving it as a csv file  
Usually the first column of the dataset is ID followed by TIME, DV, NONMEM 
specific columns and then potential covariates. Data should be sorted by ID and 
TIME.  
Table III. Explanation of parameters of an input .csv file of NONMEM. 
SYMBOL MEANING 
ID Patient number 
TIME Time since introducing tacrolimus therapy 
(independent variable) 
DV Dependent variable (concentration of 
tacrolimus in whole blood [ng/ml], predicted 
by NONMEM) 
CONC Hospital measurements of trough 
concentrations of tacrolimus in whole blood 
[ng/ml]  
CMT Compartment  1 = Depot 
2 = Central 
3 = Peripheral 
MDV Missing dependent 
variable 
1 = Missing 
concentration 
measurement 
(dosing record) 
0 = Concentration 
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measurement 
AMT Amount of drug (single dose) 
ADDL Additional doses 0 = No additional 
doses 
n = n additional 
doses 
II Inter-dose interval  
PDN Prednisone dose per day [mg] 
AGE Age [years] 
HT Height [cm] 
WT Weight [kg] 
SEX Gender 1 = Female 
0 = Male 
HB Haemoglobin [g/dl] 
RTXT The difference between the time when 
tacrolimus treatment was introduced and the 
transplantation date [days]1 
1 Instead of time = 0 on transplantation date, time is shifted to time = 0 when tacrolimus therapy is 
commenced (avoiding time < 0 when tacrolimus is given as a pre-dose before the transplantation) 
• Reviewing the data  
We made diagnostic plots of concentration vs. time, dose vs. weight and 
concentration vs. dose and identified potential outliers and mistakes in the dataset.  
• Writing a control file  
Control file is read by NONMEM and it is basically a file where you specify your 
input, output data, model characteristics and tell NONMEM what to do. We used 
two analysis methods available within the package - first order conditional 
estimation with interaction (FOCE-I) and simulation. 
• Running the NONMEM programme  
• Interpreting results  
There are two files one must check after a run in NONMEM is completed – the run 
summary which tells if there were any problems during the run and whether it 
finished successfully and the output file where the results of estimation or 
simulation are stored. 
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3.2.1 Literature model 
 
Children's Memorial Health Institute provided us with a database which included only 
trough concentrations of tacrolimus in whole blood. This means that without having blood 
samples from the whole concentration–time pharmacokinetic profile it would be 
impossible to develop a population pharmacokinetic model. Therefore, the main objectives 
were to review the literature and find an existing model that would meet the following 
criteria: 
• Paediatric kidney transplant recipients 
• Per os tacrolimus treatment 
• Large number of samples over the whole PK profile 
• Large number of patients 
After an adequate model was found an estimation was executed using the FOCE-I method 
with all the parameters fixed to the literature values (MAXEVAL = 0, METHOD =1). To 
run the process, we used ADVAN4/TRANS4 subroutines for a two-compartment model 
with first order absorption including the following basic parameters: 
• Clearance (Cl) 
• Volume of the central compartment (V2) 
• Intercompartmental clearance (Q) 
• Volume of the peripheral compartment (V3) 
• Absorption rate constant (Ka) 
Afterwards we created diagnostic plots using the R (3. 3. 2) software to compare the 
individually predicted and population predicted concentrations to observed values and see 
how good the model describes our data. Then the OFV and CWRES distribution were a 
starting point to evaluate addition of other potential covariates. 
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3.2.2 Covariate model 
 
In addition to the covariates described in the literature model we tried to identify any other 
potential covariates which could improve the performance of our model. The basis for 
doing so was investigating the relationship between a potential covariate and conditional 
weighted residuals (CWRES). Normal distribution of CWRES with the mean of 0 and 
variance 1 means that the model was performing well and there is no need to include the 
tested covariate in our model. In addition, also a drop of OFV by more than 3.84 and 
improvement of the goodness of fit plots indicated that a covariate should be included. 
Potential covariates tested were: 
• Prednisone as co-medication 
• Other co-medication 
• eGFR 
• Donor type 
• Gender 
• Age 
 
3.2.2.1 Prednisone 
 
Prednisone dose was the first covariate we tested since 91.76 % of our patients received it 
and literature review supported our intentions of including it as a covariate. Prednisone 
induces the CYP 3A isoenzymes therefore a higher tacrolimus dose is needed  (46).  
Størset et al. have included the active metabolite of prednisone, prednisolone, in their 
model (47). Since both prednisone and prednisolone have the same anti-inflammatory and 
sodium retaining potency, approximately the same duration of action after oral dose (20) 
and are interchangeable on 1 mg : 1 mg basis (48) we decided to incorporate prednisone in 
our model using the Equation 4 proposed originally by Størset et al. for prednisolone. They 
discovered that a sigmoid Emax model described an effect of prednisolone dose on 
bioavailability (F) of TAC with the maximum reduction in F being 67 % and the daily dose 
of prednisolone exerting half maximum effect was 35 mg. Their study also observed F to 
be almost 3 times higher on the first day after transplantation than on any other day despite 
the lack of clear theoretical basis (47). 
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𝐹 = (1 −
0.67∗𝑃𝑟𝑒𝑑𝑛𝑖𝑠𝑜𝑛𝑒 𝑑𝑜𝑠𝑒[𝑚𝑔]
35 mg + Prednisone dose
) ∗ 2.68(𝑖𝑓 𝑑𝑎𝑦 𝑜𝑛𝑒 𝑝𝑜𝑠𝑡 − 𝑡𝑟𝑎𝑛𝑠𝑝𝑙𝑎𝑛𝑡)   Equation  4 
Afterwards we compared the OFV of the literature model and the covariate model and 
visually inspected goodness of fit plots to decide whether prednisone should be included as 
a covariate. 
 
3.2.2.2 Co-medication 
 
To assess the impact of co-medication on ability of our model to predict tacrolimus 
concentration we calculated the median of CWRES for each drug and chose to further 
examine only those that were present at least in three data records. Secondly, we ordered 
the drugs based on the median of CWRES and focused on those with the median of 
CWRES furthest from 0 (either in positive or negative) and checked in the literature if they 
were known for changing the PK of TAC. 
 
3.2.2.3 eGFR 
 
Andrews et al. described eGFR as a potential covariate in their model where an increase in 
eGFR from 30 to 90 mL/min resulted in 19 % higher tacrolimus clearance even though the 
correlation is unclear as tacrolimus undergoes almost no renal elimination (49). Their 
model was based on data up to 6 weeks after transplant and we wanted to see if eGFR 
correlated with under- or overprediction of our model as well. Therefore, we included data 
up to 6 weeks post-transplant and used CWRES as our evaluation marker. 
 
3.2.2.4 Donor type 
 
According to Andrews et al., patients who received a kidney from a deceased donor had a 
significantly higher TAC clearance in the first 6 weeks post-transplant than recipients of a 
living donor kidney though explanation remains unclear (49). We checked the differences 
between living and deceased donors in the first 6 weeks, one year, two years, 5 years and 
more than 5 years post-transplant based on the median of CWRES for each group. 
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3.2.2.5 Gender 
 
Out of 85 patients in our study 45 were males and 40 females. We wanted to test if there is 
any difference in how well our model predicts tacrolimus concentrations when patients are 
either males or females. Again, we calculated the median of CWRES for each group and 
compared the values. 
 
3.2.2.6 Age 
 
Age was an interesting covariate to investigate from both the PK and PD point of view. 
Firstly, biological maturation could have an impact on clinical pharmacokinetics of 
tacrolimus and secondly when patients get older and become teens, they could be more 
rebellious towards their parents and doctors which could lead to non-compliance with drug 
treatment. We investigated how well our model describes tacrolimus concentrations for 
different age groups by calculating the median of CWRES for each age group. 
 
3.2.3 Validation and evaluation 
 
The final PK model was validated to show it accurately describes pharmacokinetics of 
tacrolimus in paediatric kidney transplant patients. 
3.2.3.1 Goodness-of-fit plots 
 
Routine diagnostic plots of goodness-of-fit (GOF) were drawn in R and they include 
graphical visualization of: 
• observed dependent variable (tacrolimus concentrations - DV) versus individual 
predicted concentrations (IPRED),  
• observed dependent variable (DV) versus population predicted concentrations 
(PRED),  
• conditional weighted residuals (CWRES) versus time, 
• conditional weighted residuals (CWRES) versus individual predicted 
concentrations (IPRED). 
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Ideally, all points should be as close as possible to the line of identity (x = y) in the first 
two plots whereas CWRES values should be equally distributed, N(0,1), around the zero-
slope line (y = 0).  
 
3.2.3.2 Prediction and variability corrected visual predictive check (pvcVPC) 
 
Visual predictive check was drawn in R to evaluate how accurately our model simulates 
data in comparison with the observed data. Because patients in this study had different 
dosing regimens and different expected variability within the individuals, prediction and 
variability corrected VPC was drawn to overcome these barriers. We have executed 1000 
simulations with our final PK model in NONMEM, divided the original dataset into 10 
time bins with approximately equal number of observations, calculated the 5th, median and 
95th percentile of the original data for each time bin and presented the observed data with a 
95 % simulation-based confidence interval. Ideally, the 5th, median and 95th percentile 
should align with the confidence interval from simulated datasets to verify that the 
simulated and observed data are consistent  
 
3.3 Dosing simulation  
 
We created a population of virtual patients in R and used our final PK model to simulate 
various dosing regimens of TAC in NONMEM to predict trough concentrations when 
different dosing algorithms are applied. The following dosing scenarios were evaluated 
a) Each patient was administered the same dose of 0.3 mg/kg/day divided 
twice daily in accordance with the current dosing guidelines. 
b) Dosing was adjusted for several weight bins rather than being uniform 
across the weight interval; doses ranged from 0.12 mg/kg/day to 0.75 
mg/kg/day divided every 12 hours.  
c) Improved dosing guidelines:  
1. Simulating the current dosing guidelines of 0.3 
mg/kg/day divided every 12 hours 
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2. Based on the results from 1., we calculated a 
correction factor for each 2.5 kg weight bin to get all 
the patients within the therapeutic range, then added a 
correction factor for prednisone effect and rounded 
the doses of TAC to 0.5 mg (the lowest available 
dose) 
3. Simulating the rounded doses from 2. to get the 
percentage of people within the therapeutic range 
Simulations are explained into details in the chapters 3.3.1, 3.3.2 and 3.3.2.1. 
 
3.3.1 Current dosing guidelines 
 
Tacrolimus is usually given on mg/kg basis with majority of paediatric kidney transplant 
patients receiving 0.3 mg/kg/day divided into two daily doses and the therapeutic trough 
concentration for the first month post-transplant is 10 – 15 ng/ml (34). For illustrative 
purposes we created a dataset of 100 virtual patients with weight ranging from 5 to 80 kg, 
treated with tacrolimus 0.3 mg/kg/day divided every 12 hours. Then we used our final PK 
model to perform a simulation in NONMEM with 100 iterations to see whether tacrolimus 
trough levels are within the desired therapeutic range (10 – 15 ng/ml) when the drug itself 
is administered according to the current dosing guidelines. We drew a graph in R with 
weight on x-axis and tacrolimus trough concentration on y-axis. Based on these results we 
created several weight bins with individually adjusted mg/kg dosing to improve the ratio of 
TAC trough concentrations within the recommended 10 – 15 ng/ml therapeutic window. 
We performed another simulation with 2500 virtual patients (weight ranging from 5 to 80 
kg) who received 0.12 – 0. 75 mg/kg/day divided in two daily doses, simulating it 80 
times. Another graph showing tacrolimus concentration versus weight was then drawn in R 
to better visualize the results. 
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3.3.2 Improved dosing guidelines 
 
Similarly as in chapter 3.3.1 we have performed a simulation in NONMEM (10 iterations) 
where each virtual patient received 0.3 mg/kg/day of tacrolimus in two daily doses every 
12 hours. We have increased the number of virtual patients to 150 000 and expanded the 
weight interval to 5 – 100 kg. Afterwards we divided the weight into bins of 2.5 kg, 
calculated the median DV (TAC concentration) of each bin for all iterations and then 
computed a correction factor by which the current dose of the bin should be multiplied by 
to achieve tacrolimus trough concentration of 12.5 ng/ml (mean of 10 – 15 ng/ml interval). 
 
𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 1 =
12.5 [𝑛𝑔/𝑚𝑙]
𝑚𝑒𝑑𝑖𝑎𝑛(𝐷𝑉 [𝑛𝑔/𝑚𝑙])
     Equation 5 
 
Then we assigned prednisone dose ranging from 0 to 120 mg to each weight bin of our 
virtual population and calculated the correction factor 2 derived from Equation 4. 
 
𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 2 =  
1
1 − 
0.67∗𝑃𝑟𝑒𝑑𝑛𝑖𝑠𝑜𝑛𝑒 𝑑𝑜𝑠𝑒 [𝑚𝑔]
35+𝑃𝑟𝑒𝑑𝑛𝑖𝑠𝑜𝑛𝑒 𝑑𝑜𝑠𝑒 [𝑚𝑔]
     Equation 6 
 
Finally, tacrolimus single dose (twice daily regimen) was calculated as shown in Equation 
7.   
 
𝑇𝐴𝐶 [𝑚𝑔] = 𝑊𝑇 [𝑘𝑔] ∗ 0.3 [𝑚𝑔/𝑘𝑔/𝑑𝑎𝑦] ∗ 0.5 [𝑑𝑎𝑦] ∗ 𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟1 ∗
𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟2        Equation 7 
 
The dose was then rounded to the nearest 0.5 value since tacrolimus administered in 
Children's Memorial Health Institute in Warsaw, Poland, is usually (to 98.82 % of our 
study population) given under the tradename Prograf® which is available only in 0.5 mg, 1 
mg and 5 mg capsules. Results were presented in a chart with weight on x-axis and 
prednisone dose on y-axis.  
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3.3.2.1 Validation of the improved dosing guidelines 
 
We simulated the doses taken every 12 hours which are presented in the chart (Figure 13) 
to demonstrate that we improved the current dosing guidelines and more people are within 
the desired target range of 10 – 15 ng/ml. Simulation (10 iterations) with the same virtual 
patients as in chapter 3.3.2 was performed in NONMEM. Again, we divided weight 
interval into 2.5 kg bins, calculated median DV, 50 % and 90 % interpercentile range for 
each bin and plotted weight versus tacrolimus concentration and checked whether the 
simulated values are within the desired range. 
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4 Results 
 
4.1 Population 
 
In total, after having met the inclusion criteria, 85 patients were included in our study 
cohort, demographics and clinical characteristics of which are presented in the Table IV. It 
is important to point out that age, weight and height of paediatric patients changed 
drastically from the first until the last entry data as there were entries included for up to 
11.5 years after the transplant date therefore we calculated the mean, standard deviation 
and range of demographic and clinical characteristics of patients at time 0 when tacrolimus 
therapy was introduced.  
 
Table IV. Biological characteristics of our study population. 
Parameter Mean ± SD Range (min – max) 
Number of patients 85 / 
Gender 45 males, 40 females / 
Total number of cmin 1305 / 
Number of measurements of 
cmin per ID 
15.72 ± 11.62 1 – 73 
Age [years]1 10.2 ± 4.9 1.4 – 17.9 
Weight [kg]1  29.5 ± 16.0 9.0 – 72.5 
Height [cm]1,2 126.8 ± 28.0 75.0 – 179.0 
Haemoglobin [g/dl]1,3 11.2 ± 1.5 8.2 – 14.9 
Serum creatinine [mg/dl]1  5.93 ± 3.02 0.43 – 16.90 
eGFR [ml/min/1.73 m2]1,2 13.63 ± 16.61 4.06 – 111.30  
Donor type Deceased 69  
81.18 % 
/ 
Living related  16  
18.82 % 
/ 
1 Calculated at time 0 when tacrolimus therapy was introduced 
2 Missing in 1 patient 
3 Missing in 18 patients 
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Patients were receiving TAC and other concomitant medication. Details are given in Table 
V displaying only the most commonly used drugs and the ones we found interesting to 
investigate further. It is important to point out that not everyone received the same co-
medication and for the same amount of time.   
Tacrolimus was administered per os twice daily to 84 (98.82 %) patients as the immediate-
release formulation (Prograf®) whereas 1 (1.18 %) patient was administered tacrolimus 
once a day as the prolonged-release formulation (Advagraf®).  
Prednisone dose range seems fairly wide, but one should be aware that the dose is much 
higher on the first day post-transplant and then tapered over time. 
 
Table V. Summary of the concomitant medication in our study population. 
Medication Number and % of patients 
receiving medication 
Range (min – max) 
[mg/day] 
Tacrolimus  85 (100 %) 0.5 – 20.0 
Prednisone  78 (91.76 %) 1.0 – 800.0 
Deflazacort  3 (3.53 %) 1.5 – 18.0 
Sodium bicarbonate  6 (7.06 %) 300 - 4000 
Omeprazole  31 (36.47 %) 10.0 – 70.0 
 
4.2 Population pharmacokinetic model 
 
Data entries for PopPK analysis were organized as depicted in Table VI for patient with ID 
number 2. This is a standard format for NONMEM input files. Column headings are 
explained in Table III. 
Table VI. Data entries for PopPK analysis for patient with ID number 2. 
ID TIME CONC CMT MDV AMT ADDL II PDN AGE HT WT SEX HB RTXT DV 
2 0 NA 1 1 1.5 259 12 330 9.3 128.5 23.6 1 NA 0 NA 
2 24 20.0 2 0 NA NA NA NA 9.3 128.5 23.6 1 NA 0 NA 
2 72 3.9 2 0 NA NA NA NA 9.3 128.5 23.6 1 NA 0 NA 
2 168 9.3 2 0 NA NA NA NA 9.3 128.6 23.5 1 NA 0 NA 
2 336 11.2 2 0 NA NA NA NA 9.4 128.6 23.5 1 NA 0 NA 
2 3120 NA 1 1 2.0 239 12 0 9.7 131.3 27.4 1 NA 0 NA 
2 4464 6.0 2 0 NA NA NA NA 9.9 133.9 29.9 1 NA 0 NA 
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4.2.1 Literature model  
 
Our data adequately fit a two-compartment model (Figure 3) that included first-order 
absorption and lag time as described in article study by Zhao et al. The model was 
developed based on samples collected from 50 paediatric kidney transplant patients (age 2 
– 18 years) who were treated with tacrolimus (11).  
The apparent oral clearance (CL/F) correlated with body weight (allometric scaling) and 
was higher in children with CYP3A5*1/*3 or *1/*1 genotype and lower in patients with 
high haematocrit since tacrolimus binds strongly to erythrocytes. Equation 8 describes 
apparent oral clearance. 
 
𝐶𝐿/𝐹 =  𝜃𝐶𝐿  ∗ (𝑊𝑇/70)0.75 ∗  𝜃𝐶𝑌𝑃3𝐴5𝐹𝐿𝐴𝐺1 ∗ 𝑒𝜂(𝐶𝐿) +  
            𝜃ℎ𝑎𝑒𝑚𝑎𝑡𝑜𝑐𝑟𝑖𝑡1 ∗ 𝜃ℎ𝑎𝑒𝑚𝑎𝑡𝑜𝑐𝑟𝑖𝑡2𝐹𝐿𝐴𝐺2     Equation 8 
 
  If CYP3A5*3/*3, FLAG1 = 0; if CYP3A5*1/*3 or*1/*1, FLAG1 = 1 
  If haematocrit ≥ 33%, FLAG2 = 0; if haematocrit < 33%, FLAG2 = 1 
 
We had to make some simplifications since our dataset did not include CYP3A5 genotype 
categorisation nor the haematocrit values. According to the literature most Caucasian 
people are CYP3A5 non-expressers (CYP3A5*3/*3) (11) and we assumed majority of 
patients had haematocrit values above 33 % thus simplifying Equation 8 to Equation 9.   
 
𝐶𝐿/𝐹 =  𝜃𝐶𝐿  ∗ (𝑊𝑇/70)0.75  ∗ 𝑒𝜂(𝐶𝐿) + 𝜃ℎ𝑎𝑒𝑚𝑎𝑡𝑜𝑐𝑟𝑖𝑡1   Equation 9 
 
The model also included apparent central volume of distribution, absorption rate constant, 
intercompartment clearance and apparent peripheral volume of distribution which were 
calculated as shown in Equations 10 – 13 (11). Parameter values are listed in Table VII. 
  
𝑉2/𝐹 = 𝜃𝑉2 ∗ (𝑊𝑇/70) ∗ 𝑒𝜂(𝑉2)       Equation 10
     
𝐾𝑎 =  𝜃𝐾𝑎 ∗ 𝑒𝜂(𝐾𝑎)  Equation 11 
 
𝑄/𝐹 =  𝜃𝑄  ∗ (𝑊𝑇/70)0.75 ∗ 𝑒𝜂(𝑄)      Equation 12 
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𝑉3/𝐹 = 𝜃𝑉3 ∗ (𝑊𝑇/70)   Equation 13 
 
  
    
  
 
  
Figure 3. A two-compartment model. 
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Table VII. Literature model parameter estimates (11). 
Parameter Value 
θCL [L/h] 13.9 
θV2 [L] 57.9 
θKa [h-1] 0.462 
θQ [L/h] 79.7 
θV3 [L] 966 
θlag time [h] 0.356 
θCYP3A5 2.26 
θhaematocrit1 7.11 
θhaematocrit2 1.74 
Interindividual variability  
ωCL [%] 41.9 
ωV2 [%] 132 
ωKa [%] 76.2 
ωQ [%] 89.9 
Residual variability – additive error  
σ2 3.2 
Objective function value  7933.439 
 
4.2.2 Covariate model 
 
Conditional weighted residuals (CWRES) were plotted against demographic (gender, age) 
and clinical (kidney function, haematocrit level, co-medication, donor type) variables for 
visual inspection. If the model fits the data adequately, approximately 95 % of the CWRES 
values should be within 2 standard deviations of the mean, in our case 0 ± 2 (see chapter 
1.2.2). Variables that showed a correlation with CWRES distribution were evaluated 
further. In addition, a drop of OFV by more than 3.84 and improvement of the goodness of 
fit plots indicated that a covariate should be evaluated further and potentially included in 
the final model. 
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4.2.2.1 Prednisone 
 
Inclusion of prednisone dose effect on F of TAC as described by Størset et al. (47) resulted 
in the drop of OFV from 7933.439 (original model) to 7571.193. A decrease in OFV by 
362.246 which is highly statistically significant (p < 0.001) indicates that inclusion of the 
effect of prednisone dose on F greatly improves the model. 
 
4.2.2.2 Co-medication 
 
Figure 4 illustrates how we investigated various impacts of co-medication on CWRES. 
Drugs are ordered descending by the median of CWRES values.  
 
Figure 4. Relationship between co-medication and conditional weighted residuals (CWRES).  
Numbers in the plot represent the number of data entries for the given medication.  
 
4.2.2.3 eGFR 
 
The impact of kidney function on model performance was evaluated visually using 
estimated glomerular filtration rate (eGFR). Figure 5 demonstrates how well the model 
predicts tacrolimus concentrations at different eGFR values. Ideally, purple line should 
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align with zero slope line indicating that observed tacrolimus concentrations are the same 
as predicted by the model. 
 
Figure 5. eGFR vs CWRES up to 6 weeks post-transplant.  
Purple line – data smoother to see what the data trends look like; interconnected dots belong to the same 
individuals; red dashed line, zero slope line (ideal values of CWRES); eGFR, estimated glomerular 
filtration rate; CWRES, conditional weighted residuals.  
4.2.2.4 Donor type 
 
Figure 6 displays the differences between living and deceased donors in the first 6 weeks, 
one year, two years, 5 years and more than 5 years post-transplant based on the median of 
CWRES for each group. 
 
Figure 6. Impact of the donor type over time. 
 Numbers in the plot represent the number of data entries for the given type of donor. RTX, 
transplantation date; CWRES, conditional weighted residuals. 
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4.2.2.5 Gender 
 
The differences between males and females and their impact on the performance of our 
model are depicted in Figure 7. 
 
Figure 7. Gender impact on performance of our model.  
Numbers, the number of data entries for males and females. CWRES, conditional weighted residuals. 
 
4.2.2.6 Age 
 
The performance of the model according to different age groups is presented in Figure 8.
 
Figure 8. Age groups versus CWRES.  
Numbers in the plot represent the number of data entries for the given age group. CWRES, conditional 
weighted residuals. 
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4.2.3 Validation and evaluation 
 
Our final model was validated by goodness-of-fit plots and pvcVPC. The definition of the 
final model is enclosed in Appendix - Figure 15. 
 
4.2.3.1 Goodness-of-fit plots 
 
The routine analytic goodness-of-fit plots are presented in Figure 9. 
 
Figure 9. Goodness-of-fit plots for the final PK model.  
(A) Plot of observed tacrolimus concentrations versus population predictions (PRED). Black line, line of 
identity (perfect fit); red line, data smoother. (B) Plot of observations versus individual predictions 
(IPRED). Black line, line of identity (perfect fit); red line, data smoother. (C) Plot of conditional weighted 
residuals (CWRES) versus individual predictions (IPRED). Black line, zero-slope line (perfect fit); red 
line, data smoother. (D) Plot of conditional weighted residuals (CWRES) versus time (log scale). Black 
line, zero-slope line (perfect fit); red line, data smoother. 
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4.2.3.2 Visual predictive check 
 
Figure 10 below shows a prediction and variability corrected visual predictive check 
(pvcVPC). Ideally, the 5th, median and 95th percentile (red lines) should align with the 
simulation-based confidence intervals (semi-transparent blue and red fields). 
 
Figure 10. Prediction and variability corrected visual predictive check (pvcVPC).  
Dashed red lines, 5th and 95th prediction and variability corrected observed percentile (90 % interpercentile 
range); solid red line, prediction and variability corrected observed median; semi-transparent blue fields, 
model-based prediction and variability corrected 95 % confidence intervals; semi-transparent red field, 
prediction and variability corrected model-based 95 % confidence interval; blue dots, actual prediction 
and variability corrected observations. 
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4.3 Dosing simulation 
 
4.3.1 Current dosing guidelines 
 
Simulated steady-state trough concentrations for TAC in accordance with the current 
dosing guidelines of 0.3 mg/kg/day in two daily doses are presented in Figure 11. 
 
 
Figure 11. Simulated tacrolimus steady-state trough concentrations for 0.3 mg/day/kg dosing. 
Solid red line, median of simulated trough concentrations; semi-transparent blue field, 90 % 
interpercentile range; dashed red lines, target range for tacrolimus (10 – 15 ng/ml) for early post-
transplant period. 
Next, we performed a simulation where patients with smaller body weight were 
administered higher TAC dose per kg whereas heavier patients received lower dose per kg. 
Table VIII below contains information on weight groups and doses whereas Figure 12 
visually presents the predicted trough levels of TAC. 
Table VIII. Dosing recommendation for tacrolimus. 
Weight group  
[kg] 
Tacrolimus dose 
[mg/kg/day] 
< 10 0.75 
10 – 15 0.45 
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15 – 25 0.3 
25 – 35 0.21 
35 - 50 0.15 
> 50 0.12 
 
 
Figure 12. Dosing of tacrolimus across the weight interval.  
Red dashed lines, tacrolimus target concentration (10 – 15 ng/ml); darker semi-transparent field, 50 % 
interpercentile range; brighter semi-transparent field, 90 % interpercentile range. 
 
4.3.2 Improved dosing guidelines 
 
Figure 13 is a dosing recommendation for the first months after transplantation to reach the 
target concentration of 12.5 ng/ml (10 – 15 ng/ml) where we already consider the 
limitation of available pharmaceutical forms of immediate release Prograf® (0.5 mg, 1 mg 
and 5 mg) and doses are calculated for each weight bin separately. Doses depend on weight 
and concomitant prednisone dose and are simply obtained from the chart.   
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Figure 13. Tacrolimus dosing guidelines for paediatric kidney transplant recipients for the first month after surgery when the therapeutic window for tacrolimus is 
10 – 15 ng/ml. Numbers in the coloured field represent single dose of tacrolimus in mg which needs to be taken every 12 hours. 
Example 1: A 25 kg child who underwent kidney transplantation and is starting with 
tacrolimus but does not concomitantly receive prednisone should receive 3 mg of 
tacrolimus every 12 hours. With current available formulations this would mean: 3 x 1 mg 
Prograf every 12 hours 
 
Example 2: A 25 kg child who underwent kidney transplantation and is starting with 
tacrolimus along with 60 mg of prednisone per day should receive 5 mg of tacrolimus 
every 12 hours. With current available formulations this would mean: 1 x 5 mg Prograf 
every 12 hours. 
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4.3.2.1 Validation of the improved dosing guidelines 
 
Figure 14 presents predicted tacrolimus trough concentrations in a hypothetical scenario 
where individuals are treated with TAC according to our improved dosing guidelines 
(Figure 13).  
 
 
Figure 14. Simulated tacrolimus concentrations with dosing from Figure 13 applied.  
Red dashed lines, tacrolimus therapeutic window (10 – 15 ng/ml); black solid line, median of simulated 
trough values; dark grey semi-transparent field, 50 % interpercentile range; light grey semi-transparent 
field, 90 % interpercentile range. 
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5 Discussion 
 
Developing a model from sparse trough concentration-time points is virtually impossible. 
Therefore, we had to perform a literature search of pre-developed PK models with, ideally, 
demographically comparable patient’s population receiving the same medication for the 
same condition. A two-compartment model with first order absorption and lag time defined 
by Zhao et al. (11) adequately described our data but due to insufficient information on 
CYP3A5 genotype categorisation and haematocrit values we had to simplify the model and 
assume that all patients were CYP3A5 non-expressers and had a haematocrit value above 
33 %.   
In NONMEM we used the FOCE-I analysis method and fixed parameter values to 
estimates obtained from the rich data of the study by Zhao et al. This approach is not 
always optimal and to get better estimates of the parameters we could use the $PRIOR 
method in NONMEM where sparse data are analysed under a relatively complex model 
requiring only certain key information from the rich data but the rich data themselves are 
not needed (50).  
To improve the original model by Zhao we tested prednisone dose, co-medication, eGFR, 
donor type, gender and age as potential covariates.  
91.76 % of patients received prednisone during the treatment with TAC which made it 
easier to test its statistical significance since the sample size was large enough. Hesselink 
et al. already suggested that higher TAC doses are required when prednisone is taken 
concomitantly to achieve the same target concentration range (46). We adapted the 
prednisone effect on bioavailability of TAC from Størset et al. and incorporated it into the 
model (47) which resulted in a drop of OFV by more than 360 which is statistically 
significant at p < 0.001. Therefore, we decided to include prednisone dose as a covariate in 
our model.  
Conditional weighted residuals (CWRES) are a common model diagnostic tool indicating 
model misspecification when CWRES values are not normally distributed with the mean of 
0 and variance 1. Data from the hospital included a variety of medication which was 
prescribed to patients in addition to prednisone and TAC. We have sorted them by median 
CWRES values (Figure 4) and observed the CWRES distribution. Majority of the CWRES 
values were within 0 ± 2 interval indicating that no major misspecification of the model 
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occurred. However, we examined the drugs with the highest and lowest median of CWRES 
values closely and had some difficulties with it since the percentage of people taking the 
medication was either very low, the drug was taken only for a couple of days or the 
theoretical evidence of medication altering the PK of tacrolimus was missing. To better test 
the impact of co-medication we would need a bigger sample size of patients taking them 
and for a longer period of time. Consequently, we decided not to include any of the 
additional co-medication as a covariate in our model.   
We did not observe any significant difference between the two donor types regarding their 
impact on PK of TAC up to 5 years after transplantation (Figure 6). Even though a living 
donor group had slightly greater CWRES values after 5 years post-transplant, there were 
only 3 data entries provided for this group which was not enough to further evaluate the 
impact of the donor type.  
Age (Figure 8) was also not included in the final model as the only age group showing a 
trend of greater CWRES values were patients older than 18 and there were only 2 data 
entries provided for this group. Similarly, the distribution of CWRES values for females 
and males was comparable with the median of approximately 0 (Figure 7), suggesting our 
model was not misspecified and gender was not considered as a potential covariate.   
According to Andrews et al. (49), an increase in eGFR from 30 to 90 ml/min results in  
19 % higher clearance values. When we tested eGFR as a potential covariate (Figure 5), 
the CWRES values were constantly positive, meaning that the model is slightly 
underpredicting (Equation 2) TAC concentrations for all eGFR values. If TAC clearance 
would actually increase by almost 20 %, our model would be overpredicting the 
concentration values since the increase in the clearance was not specified in the model 
itself thus CWRES values would be negative for higher eGFR values. Our findings were 
not consistent with Andrews et al. and we decided not to investigate eGFR further as a 
potential covariate.  
The performance of our model was validated by GOF and pvcVPC plots. Visual inspection 
of goodness-of-fit plots (Figure 9) of the final PK model showed that the red trend line and 
black reference line are almost aligned with each other in graph (B), (C) and (D). This 
means that our model predicts tacrolimus concentrations accurately for an individual with 
certain characteristics and that there are no trends in graphs of residuals vs. IPRED or vs. 
time which means that the model is adequate. However, the model itself is not optimally 
predicting population concentrations (assuming all individuals are typical) since there is a 
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deviation between the trend line and the reference line (graph (A)).  
pvcVPC (Figure 10) is an analytical tool to verify that the simulated and observed data are 
consistent. Our model seems to appropriately predict the median and 95th percentile values 
whereas the 5th percentile values are slightly underpredicted.   
All things considered our model is fairly robust but there are still opportunities for further 
enhancements. First of all, information on genotype and haematocrit of the studied 
population would add to the accuracy of the model since assumptions and simplifications 
of the model have been made. Secondly, the data provided was raw and was yet to be 
revised by the Children's Memorial Health Institute in Warsaw, Poland, to make sure all 
the entries in the original file were correct. This could explain some of the outliers we 
encountered in the dataset. 
The final model was used to design a dosing algorithm for the starting dose of TAC in 
paediatric kidney transplant patients. We have simulated the current treatment regime of 
tacrolimus for the first month of therapy in paediatric kidney transplant patients and 
demonstrated that it is not optimal for achieving the required concentration range as 
heavier children are overexposed and patients with lower body weight are underexposed 
(Figure 11). Dosing guidelines for children are many times derived from guidelines for 
adults and are based on scaling the dose according to the body weight alone which is not 
suitable for all medicines as it can lead to drug’s under- or overexposure as is the case with 
tacrolimus especially with its narrow therapeutic window which can lead to adverse effects 
on the one hand and absence of effect - graft rejection - on the other. A comparison of 
Figure 11 and 12 clearly favours nonuniform dosing across the weight interval over 
standard guidelines of 0.3 mg/kg/day.  
Dosing guidelines should not only be accurate but also easy to interpret. That is why we 
proposed a dosing recommendation (Figure 13) for the first months after transplantation to 
reach the target concentration of 12.5 ng/ml (10 – 15 ng/ml) where we already consider the 
limitation of available immediate-release Prograf formulations (0.5 mg, 1 mg and 5 mg) 
and doses are calculated for each 2.5 kg weight bin separately. Determining the appropriate 
dose requires no extra calculation, it can be readily obtained from the Figure 13 and then 
taken every 12 hours. The dose is dependent on individual’s weight and the concomitant 
prednisone dose as we demonstrated in our study. The chart was validated with simulations 
(Figure 14) and the median of simulated TAC trough concentrations was constantly within 
the therapeutic range.  
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We need to point out that improved guidelines are valid as a starting dose in the early post-
transplant period when the target concentration range is 10 – 15 ng/ml. After the first 
couple of months TAC target concentration is usually lower (5 – 10 ng/ml) and these 
guidelines are not applicable anymore. 
The findings of this study have to be seen in light of some limitations. Firstly, the study 
focused on Caucasian patients and secondly, 98.82 % of our patients received immediate 
release tacrolimus (Prograf®). Therefore, the results should be interpreted with caution 
when dealing with patients of other races and/or prolonged-release tacrolimus 
(Advagraf®).  
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6 Conclusion 
 
In this study we developed a population pharmacokinetic model for twice-daily immediate-
release formulation of tacrolimus in paediatric kidney transplant patients. We adapted the 
original model by Zhao et al. which adequately described our data. Information on 
CYP3A5 genotype categorisation and haematocrit values was missing in our dataset 
therefore we had to simplify the model. Our final PK model for tacrolimus given to 
paediatric kidney transplant patients was a two-compartment model with first order 
absorption defined by the following PK parameters: clearance (Cl), volume of the central 
compartment (V2), intercompartmental clearance (Q), volume of the peripheral 
compartment (V3) and absorption rate constant (Ka). We have incorporated prednisone 
dose as a covariate with a significant impact on tacrolimus pharmacokinetics, lowering its 
bioavailability by as much as 67 %. Co-medication, eGFR, donor type, gender and age 
were tested as potential covariates but were not incorporated in the final model. 
The performance of our final model was validated by GOF and pvcVPC plots and they 
confirmed that the model is fairly robust and that it adequately describes the 
pharmacokinetics of tacrolimus in paediatric kidney transplant patients.  
We simulated the current treatment regime of tacrolimus for the first month of therapy in 
paediatric kidney transplant patients and demonstrated that heavier children are 
overexposed and patients with lower body weight are underexposed. Simulations were 
performed to determine the optimal starting dose and to develop dosing guidelines. We 
prepared a dosing chart for tacrolimus dependent on weight and prednisone dose and have 
successfully validated it with simulations. However, this was in-silico study and its true 
utility would show by hopefully improving clinical outcomes of real life patients. 
Nonetheless, we have used this opportunity to advance in PopPK/PD modelling since it 
represents an invaluable resource in pharmaceutical research and development. 
For future studies and further optimization of tacrolimus dosing guidelines it would be 
interesting to see whether the number of samples per individual and sampling schedule 
should be optimized instead of routinely sampling immediately prior to the next dose thus 
measuring only trough levels. A great tool for this analysis is PopED package in R (51). 
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8 Appendix  
 
 
Figure 15. Final model code in NONMEM language. 
 
 
 
 
 
 
